VCM
NTLA icon

Versant Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Versant Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5K Sell
1,626
-469
-22% -$6.56K ﹤0.01% 1756
2026
Q1 		$26.9K Buy
2,095
+525
+33% +$6.69K ﹤0.01% 1647
2025
Q4 		$14.1K Sell
1,570
-125
-7% -$1.72K ﹤0.01% 1838
2025
Q3 		$29.3K Hold
1,695
– – ﹤0.01% 1352
2025
Q2 		$15.9K Buy
1,695
+854
+102% +$7.01K ﹤0.01% 1651
2025
Q1 		$5.98K Buy
841
+691
+461% +$6.98K ﹤0.01% 1966
2024
Q4 		$1.75K Buy
+150
New +$2.34K ﹤0.01% 2084
2024
Q3 		– Sell
-85
Closed -$1.9K – 2058
2024
Q2 		$1.9K Buy
85
+68
+400% +$1.62K ﹤0.01% 1521
2024
Q1 		$468 Sell
17
-10
-37% -$278 ﹤0.01% 1710
2023
Q4 		$823 Buy
+27
New +$776 ﹤0.01% 1566
2023
Q3 		– Sell
-20
Closed -$816 – 2016
2023
Q2 		$816 Buy
+20
New +$811 ﹤0.01% 1670

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Versant Capital Management's NTLA Position: Q2 2026 in Review

Versant Capital Management reduced its Intellia Therapeutics (NTLA) stake by 22% in Q2 2026, selling an estimated $6.56K and leaving 1,626 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1756.

Versant Capital Management first reported a position in NTLA in Q2 2023 and has held it in 11 quarters since. The position peaked at $29.3K in Q3 2025. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Versant Capital Management held 1,626 shares of Intellia Therapeutics worth $27.5K as of Q2 2026.
  • Versant Capital Management sold 469 Intellia Therapeutics shares in Q2 2026, an estimated $6.56K.
  • Intellia Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1756 holding.
  • Versant Capital Management first reported a position in Intellia Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Versant Capital Management's Intellia Therapeutics position peaked at $29.3K in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.